Table 5 Association of PSA levels with SUVmax of the primary prostatic tumour and distribution of metastasis on [18F]PSMA-1007 PET/CT
From: Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging
PSA levels (ng/mL) | p-value | |||
|---|---|---|---|---|
≤ 10 | 10–20 | > 20 | ||
n = 101 | n = 50 | n = 43 | ||
SUVmax of primary tumour (n = 187), median (IQR)a | 13.9 (7.7–22.8) | 17.4 (11.9–29.9) | 21.5 (16.2–36.3) | < 0.001 |
Regional nodes (n = 194), %(n/Total)b | 14.9% (15/101) | 18.0% (9/50) | 41.9% (18/43) | 0.001 |
Non-regional nodes (n = 194), %(n/Total)c | 5.0% (5/101) | 6.0% (3/50) | 23.3% (10/43) | 0.004 |
Bone metastasis (n = 194), %(n/Total) b | 17.8% (18/101) | 16.0% (8/50) | 32.6% (14/43) | 0.087 |
Visceral metastasis (n = 194), %(n/Total)c | 3.0% (3/101) | 2.0% (1/50) | 7.0% (3/43) | 0.51 |